News and Announcements

January 2008

Cancer Immunotherapy Program Research Scientist Leslie Cousens, PhD receives $10,000 Rhode Island Research Foundation grant to conduct preclinical studies to optimize culture conditions for ex vivo expansion of immune effect on cells.

December 2007

Cancer Immunotherapy Program opens enrollment for phase I clinical trial to test safety of investigational new drug in patients with advanced Non-Small Cell Lung Cancers.

September 2007

Cancer Immunotherapy Program receives $600,000 grant award from the FDA Orphan Drug Development Program and NCI for phase I clinical trial to test safety of investigational drug in advanced Non-Small Cell Lung Cancer patients.

March 2007

Cancer Immunotherapy Program Investigational New Drug application (BB-IND 13282) for anti-CD3 x cetuximab bispecific antibody-armed activated T cells cleared by FDA to begin phase I testing.